Summary: This trial tested the hep C treatment sofosbuvir / simeprevir on patients who have had liver transplants. 88% of patients achieved sustained virologic response/”cure”.
Summary: With as many as 1700 eligible hep C patients in Canadian correctional facilities, Correctional Service of Canada (CSC) has decided to add only another 50 patients to its current target of 240 in treatment yearly.
Summary: Galexos (simeprevir) + Sovaldi (sofosbuvir) for 12 weeks is effective when treating those with hep C genotype 1, non-cirrhotic patients, including those with Q80K (97% with 12 weeks of treatment; 83% with 8 weeks).
- Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen
Summary: This “real-world” study evaluated treatment for patients who’s previous treatment failed. After taking daclatasvir (DCV) plus pegylated interferon and ribavirin (PR), with or without asunaprevir, and failing to achieve SVR/cure, trial subjects were retreated with sofosbuvir and simeprevir for 12 weeks. This retreatment was successful and cured all but 2 patients. However, the study showed that longer treatments with ribavirin as well may be required.
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
Summary: This trial indicated that the treatment daclatasvir, sofosbuvir, and ribavirin, a combination for all hep C genotypes, was safe for and well tolerated by patients with advanced cirrhosis or virus recurrence after a liver transplantation.
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Summary: This trial concluded that the treatment daclatasvir and sofosbuvir with ribavirin was successful (90% overall, 86% in patients with cirrhosis) after 12 or 16 weeks of treatment for hep C genotype 3 patients with advanced liver disease, regardless of their past hep C treatment experiences.
Summary: This study set out to assess patient-reported general health and emotional well-being outcomes of the hep C treatment sofosbuvir / velpatasvir when compared with a placebo. The results showed that after only 4 weeks on sofosbuvir / velpatasvir, patients experienced improvements in general health and emotional well-being. Those taking the placebo reported no improvement.
Summary: Hepatitis C is hard on patients post liver transplantation. This study looked at Harvoni (sofosbuvir/ ledipasvir) on those post liver transplant and found that the treatment is safe, highly effective, and well tolerated by those patients post liver transplantation.